Wellness Clinic Hervey Bay

29/05/2026

20/05/2026

Taurine is one of the most studied amino acids in metabolic research and one of the least discussed outside it.

The 2024 Tzang meta-analysis in Nutrition & Diabetes pooled data from randomized controlled trials of taurine supplementation and measured every major marker in the metabolic syndrome cluster. The results are more consistent and more clinically meaningful than most people realize.

Taurine is a sulfur-containing amino acid. The body synthesizes it from cysteine, but endogenous production does not always meet demand, which is why it is classified as conditionally or semi-essential. It is concentrated in the heart, brain, retina, and skeletal muscle. Plasma and tissue taurine levels are consistently lower in people with type 2 diabetes, obesity, and cardiovascular disease than in healthy controls, a pattern documented across multiple populations.

The 2024 meta-analysis pulled from randomized trials using doses between 0.5 and 6 grams per day. Against placebo, taurine supplementation significantly reduced systolic blood pressure by 4 mmHg. Diastolic blood pressure fell by 1.5 mmHg. Triglycerides dropped by 18.3 mg/dL. Total cholesterol fell by 8.3 mg/dL and LDL cholesterol by 6.5 mg/dL. Fasting glucose decreased by 5.9 mg/dL. The HOMA-IR index, a measure of insulin resistance, fell by 0.69 units. Fasting insulin decreased by 1.5 mU/L. HbA1c trended down by 0.34 percent, a borderline signal. Every endpoint moved in the direction that favors metabolic health. No effect on body weight or BMI, which actually strengthens the mechanistic case because the benefits are not mediated by weight loss.

For context on magnitude, a 4 mmHg systolic reduction is roughly what you would expect from first-line antihypertensive monotherapy at standard doses. An 18 mg/dL triglyceride drop is comparable to what EPA/DHA at 2 to 4 grams per day produces. A 0.69 HOMA-IR reduction is a substantial insulin sensitivity improvement. These are not marginal biomarker shifts. They are clinically relevant changes hit by a single amino acid with no observed safety signal.

The mechanisms that map to these outcomes are well characterized in the literature. Taurine enhances endothelial nitric oxide availability and modulates vascular tone, which plausibly explains the blood pressure reduction. It conjugates with bile acids in the liver and promotes f***l bile acid excretion, increasing hepatic demand for cholesterol as substrate and reducing circulating cholesterol and triglyceride loads. It appears to support pancreatic beta-cell function and improve insulin signaling at peripheral tissues, which maps onto the observed improvements in fasting glucose, fasting insulin, and HOMA-IR.

The caveats worth knowing. Trial sizes have generally been modest, typically 20 to 100 participants per arm. Durations have ranged from days to a year, and most are in the weeks-to-months range, so we do not have long-duration hard cardiovascular endpoint data from randomized trials. Populations skew toward metabolic syndrome, type 2 diabetes, obesity, and hepatic dysfunction rather than the healthy general population. Effects in healthy individuals without metabolic impairment may be smaller or harder to detect. A 2025 meta-analysis in overweight and obese adults identified 3 grams per day as the threshold below which glycemic improvements become inconsistent, suggesting dose matters.

Practically, most trials showing meaningful effects used 3 grams per day, usually in divided doses with meals. Taurine is classified as generally recognized as safe by the FDA. Adverse events in the meta-analysis were statistically indistinguishable from placebo and limited to mild gastrointestinal complaints, headaches, and transient fatigue. As with any intervention in people on antihypertensive medication, diabetes medication, or with liver or kidney disease, talk to a clinician before adding it.

The broader point. Taurine has meta-analysis-level evidence for improving blood pressure, lipids, glycemic control, and insulin sensitivity simultaneously, with no weight or safety trade-offs. It is remarkable how little that data shapes the way this amino acid is discussed.

Tzang CC, et al. Nutr Diabetes. 2024;14(1):29. Guan L, Miao P. Eur J Pharmacol. 2020;885:173533. Ran L, et al. Nutrients. 2025;17(1):4.

16/05/2026

Scientists have uncovered why men develop more severe gum disease and tooth decay than women. The key difference comes from a stronger inflammatory response driven by interleukin-1 beta, an immune signaling protein that becomes highly active in male gums during periodontitis. Analysis of thousands of human samples showed that men consistently produce higher levels of this molecule in the fluid between the teeth and gums, where infection and inflammation begin. This heightened response accelerates tissue breakdown, making bone loss and tooth damage more pronounced once disease starts.

Mouse studies confirmed the same pattern. Male animals secreted far more interleukin-1 beta than females, and when researchers blocked this pathway using an experimental inflammasome-targeting drug, inflammation and bone loss dropped sharply. However, this effect vanished when the te**es were removed, showing that male reproductive hormones help drive the overactive immune response. Female mice did not rely on this pathway, pointing to entirely different biological mechanisms behind gum disease in women.

The findings suggest future dental treatments may need gender-specific approaches. Targeting the inflammasome could offer meaningful protection for men, while separate biological pathways must be mapped to understand disease progression in women. This research challenges long-held assumptions that behavior alone explains gum disease differences.

Research Paper 📄
DOI: 10.1073/pnas.2507092122

09/05/2026

For 50 years, eggs were treated like a cardiovascular threat. The 1960s dietary guidelines capped cholesterol intake at 300mg per day. Two eggs put you at the limit. The advice moved millions away from the food, and away from a nutrient profile we didn't fully appreciate at the time.

A new study from Loma Linda University followed 39,498 adults age 65 and older for 15.3 years. The team linked Adventist Health Study-2 dietary records with Medicare diagnoses. Over that window, 2,858 participants developed Alzheimer's disease.

The dose-response was clean.
Eating eggs 1 to 3 times a month: 17% lower incidence vs never-eaters.
2 to 4 per week: 20% lower.

5 or more per week, roughly one a day: 27% lower.
The mechanism story isn't new, but the cohort scale and 15-year follow-up are. Eggs are the densest natural source of choline in the American diet. One large egg supplies roughly 33% of the daily choline requirement. Choline is the substrate for acetylcholine, the neurotransmitter that drops in Alzheimer's. Donepezil, the most prescribed Alzheimer's drug, works by blocking acetylcholine breakdown. The disease is partly defined by cholinergic neuron loss.

Egg yolk also delivers lutein and zeaxanthin. These are the only two carotenoids that cross the blood-brain barrier and accumulate in cortical tissue. Higher tissue levels track with better processing speed and memory across multiple older-adult cohorts. Yolk also contains DHA, primarily in phospholipid form. Phospholipid DHA enters the brain more efficiently than DHA in triglyceride form, which is the dominant form in fish oil capsules.

Now the caveats, because they matter.
This is observational. Causation cannot be drawn from a cohort study. The Adventist Health Study-2 cohort skews heavily vegetarian and health-conscious, so people who eat eggs in this cohort do not look like the average American egg-eater. The "never eats eggs" comparison group is largely vegan, which is its own dietary pattern with its own complications. Reverse causation also has to be considered. People in early Alzheimer's often change eating patterns before diagnosis. Some of the apparent protection could be that healthier brains keep eating eggs, not the other way around.

The mechanism story I outlined above is supported by adjacent literature, not by this paper. The study did not measure choline status, lutein levels, or DHA in tissue. It measured eggs in, dementia out.

What we can say honestly: in a 40,000-person cohort followed for 15 years, egg intake tracked with substantially lower Alzheimer's incidence in a dose-response pattern. The mechanism is biochemically plausible, supported by other lines of evidence, and consistent with what we know about acetylcholine and brain carotenoid status. The randomized trial that would prove causation has not been run.

The practical version: if you are over 50 and not allergic, eating an egg most days has stronger evidence behind it for brain health than most products marketed for the same goal. Five days a week was the dose with the lowest risk in this cohort. Even 1 to 3 per month showed measurable benefit.

For 50 years the question was whether eggs were dangerous to your heart. The data behind that fear was always weaker than the guidelines made it sound, which is why the 2015 Dietary Guidelines for Americans quietly removed the 300mg cap. The brain question got asked too late.

Oh et al., J Nutr, 2026 (DOI: 10.1016/j.tjnut.2026.101541)

09/04/2026

24/03/2026

B12 + Folate + B6: are the methylation triad 🧬🫀🧠

When one is low, the entire pathway can bottleneck.

These three B-vitamins work as a tightly linked system that drives one-carbon metabolism, the biochemical process behind DNA synthesis, red blood cell production, neurotransmitter balance, and homocysteine regulation.

That’s why B12, folate, and B6 are often discussed together, not as isolated nutrients, but as a functional triad supporting cardiovascular, neurological, and metabolic health.

Why this combo matters
• Supports healthy homocysteine metabolism (a cardiovascular risk marker)
• Required for DNA synthesis and repair
• Supports red blood cell formation (distinct from iron)
• Plays a key role in nerve function and energy metabolism

RDAs vs real-world needs ⚖️

RDAs are designed to prevent overt deficiency in the general population, not necessarily to optimize function in people with:
• Elevated homocysteine
• Malabsorption issues
• Increased demand (pregnancy, aging, stress)
• Certain dietary patterns (low animal foods, restricted diets)

As a result, some individuals require supplemental doses above the RDA, under appropriate guidance.

Practical protocol:
Baseline intake (RDA level):
• Vitamin B12: 2.4 mcg/day
• Folate: 400 mcg DFE/day (600 mcg DFE during pregnancy)
• Vitamin B6: 1.3–1.7 mg/day

Common supplemental ranges used clinically (not required for everyone):
• B12: 25–500 mcg/day (higher doses often used for deficiency or absorption issues)
• Folate (B9): 400–800 mcg DFE/day
• B6: 5–25 mg/day

⚠️ Important considerations
• High folate intake can mask a B12 deficiency, especially in older adults
• B6 has an established upper limit. Chronic megadoses may not be appropriate
• These vitamins work best together, not in isolation

Who may benefit most
• Individuals with elevated homocysteine
• Older adults or those with reduced B12 absorption
• Pregnancy and pre-conception (folate is critical)
• People with fatigue, anemia, or confirmed deficiencies